Recursion Pharmaceuticals (RXRX) Stock Price
$4.65 0.4%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
3 -
Technical
4
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals. Scores are designed to reflect relative strength or weakness across these factors, helping users compare companies and track changes over time.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals' last quarter revenue was $14.7M, a significant increase of 226.9% from the previous quarter and a slight year-over-year growth of 2.3%. Despite this positive revenue trend, the company's gross profit was -$7.1M, showing an improvement of 14.5% from the previous quarter but a drastic decrease by -637.5% on a yearly basis. The operating income profit stood at -$191.4M, marking a decrease by -4.1% from the previous quarter and by -90.3% year over year.
The EBITDA ratio for the last quarter was -12.98 which indicates negative profitability or high debt levels.
Stock Price
The current stock price is $4.91 with an RSI value of 53 indicating that it is neither oversold nor overbought in terms of technical analysis indicators.The stock has been underperforming with a decline of -14.9% in the last month and -27.8% on a yearly basis.The stock's price is also below its 200-day moving average ($5.97), suggesting that it may be currently undervalued.
Alternative Data Signals
Web traffic for Recursion Pharmaceuticals shows about 68517 visitors per month, however it has decreased by -5.% month over month.Job openings have also decreased to only 26 positions (-16.% MoM).The business outlook among employees seems neutral as approximately half (52%) report having positive expectations despite being lower than last year (-26.% YoY).
Social media following shows considerable growth especially on Twitter where followers increased by more than double (82.% in the last 90 days).
Conclusion
In conclusion, despite some positive aspects like revenue growth and social media following, Recursion Pharmaceuticals' stock performance is bearish due to negative profitability ratios, decrease in gross profit and operating income as well as a declining stock price.
Note: This AI Stock Analysis is based on data as of September 20. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $4.65, will... Sign up to access price prediction.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$19.3 0.9% |
7 |
 |
Inovio Pharmaceuticals INO |
$2.42 0.6% |
2 |
 |
Moderna MRNA |
$24.22 1.6% |
4 |
 |
Anavex Life Sciences AVXL |
$8.64 1.7% |
5 |
 |
BridgeBio Pharma BBIO |
$49.57 1.2% |
6 |
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 68517 monthly visitors to recursion.com.
-
Web Traffic
68517
-
Change from Previous Month
5.1%
Twitter Followers
Recursion Pharmaceuticals has 15,361 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.4% over the last month.
-
Twitter Followers
15361
-
Daily Change
0.1%
-
1 Month Change
0.4%
-
3 Month Change
4.1%
Facebook Engagement
Recursion Pharmaceuticals has engaged 7 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
7
-
Daily Change
36.4%
-
1 Month Change
30%
-
3 Month Change
22.2%
Youtube Subscribers
Recursion Pharmaceuticals has 22,300 subscribers on its main Youtube channel, up by 14.4% over the last month.
-
Youtube Subscribers
22300
-
Daily Change
0%
-
1 Month Change
14.4%
-
3 Month Change
467.4%
Job Postings
Recursion Pharmaceuticals has an estimated 23 open job postings, which is down -4.2% over the last month.
-
Job Postings
23
-
Daily Change
0%
-
1 Month Change
4.2%
-
3 Month Change
28.1%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
100%
-
1 Month Change
0%
-
3 Month Change
100%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 52 out of 100 (neutral).
-
Business Outlook
52
-
Change from Previous Month
4%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
¤0
-
Net Income
¤0
-
Earnings per Share
¤0
-
Free cash flow
¤0
-
EBITDA
¤0
-
EBITDA Ratio
-
Total Assets
¤0
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $4.65.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2B.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $4.61 in 2026. Starting from the current price of $4.65, this represents a 0.8% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.